since uremic toxins in the middle molecule range have been postulated to be responsible for erythropoiesis suppression in end-stage renal disease , and in addition , insufficient erythropoietin production and the clearance of some middle molecular weight substances is six times greater with capd than with hemodialysis , it appears that capd can normalize the hematocrit in patients with end-stage renal disease who were anemic on other modalities with little or no change in serum creatinine , provided the remnant kidneys are capable of producing sufficient erythropoietin .
C0022661
end-stage renal disease
C0022646
kidneys